Case Studies

A pharmaceutical company developing a new treatment for a rare neurodegenerative disease had to set very strict eligibility criteria for its clinical trials. […]

A leading pharmaceutical company wanted to distribute its approved product for the treatment of a rare congenital disease into new markets where it has not yet received regulatory approval. […]

A pharmaceutical company based in North America received EMA marketing approval for its bioequivalent product for an ultra-rare disease. […]